Physician profile
Daniel K Benson
NPI 1851770465
$879.77
in general payments reported to CMS, 2019-2025
22 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $148 · 2021: $11.31 · 2022: $158 · 2023: $57.61 · 2024: $117 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $107.11 | 2019-2025 | Evenity |
| Glaxosmithkline, LLC. | $67.53 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $64.54 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Bioventus LLC | $55.46 | 2019-2020 | |
| Hologic Sales and Service, LLC | $47.32 | 2025 | Coolseal Generator |
| Lilly USA, LLC | $47.18 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $38.31 | 2019-2020 | |
| Abbvie INC. | $35.97 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.91 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $30.75 | 2022-2024 | |
| Pfizer INC. | $29.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $28.03 | 2019-2022 | |
| Astellas Pharma US INC | $20.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.20 | 2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.49 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.85 | 2019 | |
| Mylan Specialty L.P. | $14.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.65 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.